- Shares of Neovasc Inc. (NASDAQ:NVCN) soared nearly 37% after the company announced that it had submitted a premarket approval application to the U.S. Food and Drug Administration for Neovasc Reducer, used in treatment of refractory angina
- Shares of Viveve Medical, Inc. (NASDAQ:VIVE) jumped 46.5% after the company announced that it has regained compliance with Nasdaq listing rules
- Shares of Seadrill Limited (NYSE:SDRL) rose 7.2% after the company reported that it has received a 3-year contract for AOD II and AOD III, which is expected to be $98 million and $101 million in value
- Shares of Urovant Sciences Ltd. (NASDAQ:UROV) rose 18.4% after the company reported submission of New Drug Application for Vibegron, used for the treatment of overactive bladder
Neovasc Inc. (NVCN): Free Stock Analysis Report
Seadrill Limited (SDRL): Get Free Report
Viveve Medical, Inc. (VIVE): Free Stock Analysis Report
Urovant Sciences Ltd. (UROV): Free Stock Analysis Report
Original post
Zacks Investment Research